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Abstract
HIV-infected individuals may experience fever episodes. Fever is an elevation of the body temperature accompanied by
inflammation. It is usually beneficial for the host through enhancement of immunological defenses. In cultures, transient
non-physiological heat shock (42–45uC) and Heat Shock Proteins (HSPs) modulate HIV-1 replication, through poorly defined
mechanisms. The effect of physiological hyperthermia (38–40uC) on HIV-1 infection has not been extensively investigated.
Here, we show that culturing primary CD4+ T lymphocytes and cell lines at a fever-like temperature (39.5uC) increased the
efficiency of HIV-1 replication by 2 to 7 fold. Hyperthermia did not facilitate viral entry nor reverse transcription, but
increased Tat transactivation of the LTR viral promoter. Hyperthermia also boosted HIV-1 reactivation in a model of latently-
infected cells. By imaging HIV-1 transcription, we further show that Hsp90 co-localized with actively transcribing provirus,
and this phenomenon was enhanced at 39.5uC. The Hsp90 inhibitor 17-AAG abrogated the increase of HIV-1 replication in
hyperthermic cells. Altogether, our results indicate that fever may directly stimulate HIV-1 replication, in a process involving
Hsp90 and facilitation of Tat-mediated LTR activity.
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Introduction
Fever is a physiological process induced by endogenous pyretics
(IL-6, IL-1b, TNFa) in response to stresses such as pathogen
infection. It consists in hyperthermia, an elevation of the body
temperature to 38–40uC, associated with an inflammatory state.
Fever is generally beneficial for the host, triggering multiple events
that lead to the strengthening of immunological defenses. For
instance, hyperthermia increases dendritic cells (DC) maturation,
migration and antigen presentation [1]. Hyperthermia positively
impacts cytokine and antibody production by lymphocytes, and
enhances their migration to lymph nodes [2], [3]. Hyperthermia
also intensifies cytotoxic activity of Natural Killer cells and
phagocytosis by macrophages [4], [5]. Together, these events
explain why fever is often associated with better disease outcome [2].
Temperature has various consequences on viral replication.
Infection at 41uC inhibits the replication of some human viruses
such as Poliovirus, Herpes Simplex Virus type 1 and Measles Virus
[6]. Heat shock inhibits Vesicular Stomatitis Virus and Mayaro
Virus replication [7], [8]. In contrast, hyperthermia promotes
infection by Rotavirus, Dengue Virus, Epstein-Barr Virus, Human
Cytomegalovirus and plant viruses [9], [10], [11], [12], [13].
HIV-1-infected patients can experience fever at various stages of
the disease. During acute infection, HIV-1 replication is intense,
viral loads reach very high levels, and patients are subjected to
fever and strong inflammation. Opportunistic infections, which are
frequent at the final stages of AIDS, can also induce fever. They
directly impact HIV-1 replication, and treating them significantly
reduces viral loads [14]. Several millions of HIV-1-positive
patients, the majority of which not receiving any treatment, also
suffer from tuberculosis or malaria [15], [16]. The two causative
pathogens induce fever episodes, and are associated with increased
HIV-1 viral loads [17], [18], [19], [20], [21]. Fever may thus
modify the environment for HIV-1 replication, either in a positive
or a negative way. The relative contribution of direct effects of co-
infecting pathogens, inflammation, and elevated temperature to
this process is not clearly understood. The role of inflammation on
HIV-1 pathogenesis has been widely documented [22], [23], [24],
[25]. Inflammation and immune activation represent a driving
force for CD4+ T cell depletion, facilitation of viral replication,
and AIDS progression [23], [24], [25]. Immune activation also
likely impacts the establishment of viral persistence [26]. In
culture, pro-inflammatory cytokines such as IL-1b, IL-6 and
Tumor Necrosis Factor a (TNFa) favor HIV-1 replication [27],
[28], [29], [30]. Knowledge about the role of temperature on
HIV-1 replication remains fragmented. Previous research has
mainly been focused on heat shock, a transient and non-
physiological treatment (a few minutes to a few hours) at 40–
45uC, rather than on hyperthermia, an incubation at 38–40uC for
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up to a few days. Heat shock stimulates HIV-1 production in
latently infected cell lines [31], [32] and in Peripheral Blood
Mononucleated Cells (PBMCs) [33]. An increased temperature
also enhances plasma membrane fluidity and might facilitate viral
entry [34]. A precedent work, aimed at characterizing thermo-
sensitive HIV-1 integrase mutants, did not report any viral
increase at 7 days post infection (p.i.), at 39.5uC, using a high
Multiplicity of Infection (MOI), in CEM cells [35].
Heat Shock Proteins (HSPs) are induced in response to stresses
and act as chaperones, helping the folding of proteins and
preventing their aggregation. HSPs are overexpressed in many
types of tumoral cells, like multiple myeloma, breast or prostate
cancer cells [36], [37], [38]. HSPs also have important roles in
both innate and adaptive immunity [39]. Extracellular HSPs
stimulate cytokine production by DCs. HSP-bound peptides can
be endocytosed by DCs and other Antigen Presenting Cells
through interaction with the CD91 receptor, and participate to
antigen cross-presentation [39]. These properties led to the use of
HSPs as adjuvants in vaccine development [40]. Several studies
indicated that HIV-1 induces the synthesis of some HSPs such as
Hsp27 or Hsp70 [41], [42]. Hsp70 is found in virions and might
interfere with Vpr functions [42], [43], [44], [45], [46]. Hsp40 and
Hsp70 have been suggested to regulate Nef activity [47]. Recently,
it has been reported that Hsp90 and the transcription factor HSF-
1 can both increase HIV-1 transcription [48], [49]. Hsp90 was
also shown to rescue the impaired replication of ritonavir-resistant
viruses [50]. In these studies, the role of HSPs in HIV-1 replication
was mainly investigated through over-expression or depletion
experiments, whereas the direct impact of temperature on HSPs
levels and HIV-1 infection was not characterized. Overall, the
importance of HSPs for HIV-1 replication is still not fully
elucidated, and the precise role of temperature remains unknown.
We examined here the effect of physiological, fever-like
temperature (39.5uC) on several steps of HIV-1 life cycle. We show
that hyperthermia enhanced HIV-1 replication in primary CD4+
lymphocytes and cell lines. Transactivation of the Long Terminal
Repeat (LTR) promoter by Tat, and viral reactivation in a model of
latency, were both more potent at 39.5uC than at 37uC.
Hyperthermia increased Hsp90 co-localization with actively tran-
scribing HIV-1 provirus, suggesting a direct effect of this cellular
protein on viral gene expression. Our study suggests that fever
episodes may promote HIV-1 replication in infected individuals.
Results
Enhanced HIV-1 replication in CD4+ T cells grown at 39.5uC
We first analyzed the effect of hyperthermia on HIV-1
replication in Jurkat lymphoid cells and in primary CD4+ T
lymphocytes. After 2 hours of infection at 37uC, cells were
cultivated either at 37uC or 39.5uC (Fig. 1A). Viral spread was
then followed by measuring the appearance of Gag+ cells by flow-
cytometry at different time points. A representative experiment in
Jurkat cells, using different MOI (0.1 and 1 ng Gag p24/ml/106
cells), indicates that HIV-1 replication was more rapid and
efficient at 39.5uC than at 37uC (Fig. 1B). In a compilation of
independent experiments, hyperthermia increased HIV-1 replica-
tion by 4 fold (Fig. 1C). In some experiments, when a higher MOI
was used, the differences between the two temperatures were
attenuated, probably because viral replication reached saturation
levels at both 37uC and 39.5uC (not shown). Similar results were
obtained upon infection of primary CD4+ T cells (Fig. 1D), even if
the effect of hyperthermia was less marked (2.5 fold increase,
Fig. 1E). Depending on the experiments, the peak of infection was
either higher (Fig. 1D, donor 1) or occurred earlier (Fig. 1D, donor
2) under hyperthermic conditions. Thus, hyperthermia increases
HIV-1 replication in both Jurkat and primary CD4+ T cells.
We then examined how cells responded to hyperthermia in the
absence of infection. The growth and viability of primary CD4+ T
cells and Jurkat cells were not detectably influenced by hyperther-
mia (Fig. 2A and not shown). Hyperthermia significantly increased
the amount of Hsp70 and Hsp90 in CD4+ T cells, as assessed by
Western Blot (Fig. 2B). The surface levels of viral receptors (CD4
and CXCR4), Major Histocompatibility Complex class I (MHC-I)
and HLA-A2, the activation marker CD69, and adhesion molecules
ICAM-1 and LFA-1 (CD11a and CD18 chains), were similar at
37uC and 39.5uC (Fig. 2C). This suggests that hyperthermia does
not profoundly alter the behavior of CD4+ T lymphocytes, with
non-specific consequences on HIV-1 replication.
Hyperthermia increases HIV-1 single-cycle infection but
not lentivector transduction
We then asked if hyperthermia affected infection with single-
cycle HIV-1. Jurkat cells were exposed to increasing doses of
Denv(VSV), a VSV-G-pseudotyped, env-deleted HIV-1 strain. Gag
levels were assessed 24 hours later by flow-cytometry (Fig. 3A). At
various viral inputs, the fraction of Gag+ cells was about 3 times
greater at 39.5uC than at 37uC. Similar results were observed in
P4C5 cells, a reporter HeLa cell line expressing CD4, CCR5, and
harboring an HIV-1 LTR-lacZ cassette. Hyperthermia increased
single-cycle infection with Denv(VSV), assessed by measuring b-
Galalactosidase activity (Fig. 3B) or Gag levels (not shown). We
then tested a panel of viral strains with different tropisms.
Hyperthermia increased infection by either the64 strain NL4-3,
the R5 strain NLAD8, or the dual-tropic primary isolate 132W, by
4 to 7 fold in P4C5 cells (Fig. 3C). Therefore, the effect of
hyperthermia is independent of the route of entry and of co-
receptor usage. We then performed a temperature ‘‘titration’’
experiment. We infected P4C5 cells at temperatures ranging from
37uC to 40uC (Fig. 3D). Infection began to increase at 38uC
(almost 2 fold), and was further enhanced at 39uC, 39.5uC and
40uC (6–7 fold).
In contrast, hyperthermia did not augment transduction of
P4C5 and Jurkat cells with an HIV-1 lentivector (LV-GFP)
(Fig. 3E). With this lentivector, GFP expression is driven by the
Author Summary
Fever is a complex reaction triggered in response to
pathogen infection. It induces diverse effects on the
human body and especially on the immune system. The
functions of immune cells are positively affected by fever,
helping them to fight infection. Fever consists in a
physiological elevation of temperature and in inflamma-
tion. While the role of inflammatory molecules on HIV-1
replication has been widely studied, little is known about
the direct effect of temperature on viral replication. Here,
we report that hyperthermia (39.5uC) boosts HIV-1
replication in CD4+ T cells. In single-cycle infection
experiments, hyperthermia increased HIV-1 infection up
to 7-fold. This effect was mediated in part by an increased
activation of the HIV-1 promoter by the viral protein Tat.
Our results also indicate that hyperthermia may help HIV-1
to reactivate from latency. We also show that the Heat
Shock Protein Hsp90, which levels are increased at 39.5uC,
mediates in a large part the positive effect of hyperthermia
on HIV-1 infection. Our work suggests that in HIV-1-
infected patients, fever episodes may facilitate viral
replication.
Fever and HIV
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Figure 1. Hyperthermia enhances HIV replication. A: Experimental Outline. Jurkat or primary CD4+ T cells were infected with HIV-1 NL4-3 for
2 hours at 37uC and grown at either 37uC or 39.5uC for up to 10 days. B, D. Representative experiments with Jurkat and primary CD4+ T cells,
respectively. The levels of intracellular Gag were measured by flow cytometry at the indicated time points. C, E: Mean 6 SD of 5 independent
experiments in Jurkat and primary CD4+ T cells, respectively. The area under the curve was calculated for all time points in Jurkat cells, and for time
points occurring until the appearance of the peak at 39.5uC in primary CD4+ T cells. Statistical significance was assessed by the Wilcoxon test.
p,0.05(*).
doi:10.1371/journal.ppat.1002792.g001
Fever and HIV
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CMV promoter, independently of Tat, suggesting that hyperther-
mia may induce its effects during or after HIV-1 transcription.
Hyperthermia enhances Tat transactivation of the LTR
To gain further insight into the underlying mechanism of
hyperthermia-mediated increased infection, we examined several
steps of HIV-1 replication cycle. We first asked whether
hyperthermia affects the half-life of cell-free viral particles after
release. We incubated virions (produced at 37uC) at 37uC or
39.5uC for various periods of time (15 min to 24 hours). The
infectivity of the viral preparations was then measured on P4C5
reporter cells. Incubation at 37uC led to a rapid drop of infectivity,
with a half-life of about 2.5 hours. This half-life was slightly, but
not significantly, decreased at 39.5uC (Fig. S1A).
A previous study suggested that a higher temperature of infection
enhances membrane fluidity and might thus facilitate viral entry
[34]. To quantify HIV-1 entry in Jurkat cells, we used a virion fusion
assay, which allows to discriminate cytoplasmic access of viral cores
from endosomal capture [51], [52], [53]. This assay consists in the
use of viruses containing a b-lactamase-Vpr (Blam-Vpr) protein
chimera. The successful cytoplasmic access of Blam-Vpr as a result
of fusion, after 2 hours of infection, is monitored by the enzymatic
cleavage of CCF2-AM, a fluorogenic substrate of b-lactamase
loaded in target cells. This assay was previously validated as being
linear and able to detect differences in the 2-fold range [51], [52]. A
typical experiment, with two different MOI, is represented in
Fig. 4A. Using this system, we did not detect any significant effect of
hyperthermia on viral fusion and access to the cytoplasm (Fig. 4B).
Figure 2. Cell growth and expression of Hsp70, Hsp90, and surface molecules in hyperthermic T cells. A: Primary CD4+ T cells were
grown at 37uC or 39.5uC for 3 days. Cell growth was assessed every day by direct counting of living cells (Trypan blue exclusion). B: Primary CD4+ T
cells were incubated 8 hours at 37uC or 39.5uC. Cell lysates were collected and probed by Western Blot for Hsp90, Hsp70 and Actin. C: Primary CD4+ T
cells were grown at 37uC (blue line) or 39.5uC (red line) for 3 days. Cells were stained for the indicated surface markers and fixed in PFA. Isotype-
matched monoclonal antibodies were used as negative controls (grey line).
doi:10.1371/journal.ppat.1002792.g002
Fever and HIV
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We then asked if HIV-1 reverse transcription was influenced by
hyperthermia. Using an enzymatic in vitro cell-free assay, we
monitored the reverse transcriptase (RT) activity of HIV-1 virions.
Elevation of the temperature from 37uC to 39.5uC did not affect
the enzymatic activity of RT (Fig. 4C), which is consistent with
earlier studies [54], [55], [35]. To quantify reverse transcription in
the context of infected cells, Jurkat cells were exposed to single-
cycle virus, at two MOI. The levels of ‘‘early’’ and ‘‘late’’ RT
products were determined by quantitative PCR at 8 hours p.i.. As
expected, levels of viral DNA products correlated with the viral
input, and the addition of Nevirapine (NVP), an RT inhibitor,
almost completely blocked viral DNA synthesis (Fig. 4D). Hyper-
thermia had no effect on the levels of early or late RT products in
infected cells, at 8 hours p.i. and other time points (Fig. 4D and
not shown). Together, these results strongly suggest that hyper-
thermia acts after viral access to the cytoplasm and reverse
transcription.
The lack of effect of a high temperature on LV-GFP
transduction (Fig. 3) suggested a possible impact of hyperthermia
on HIV-1 transcription. To test this hypothesis, we transfected
HeLa cells carrying an integrated LTR-Luciferase cassette (HeLa
LTR-Luc cells), with increasing amounts of a Tat-expressing
plasmid (pcDNA-Tat-Flag). HeLa LTRDTAR-Luc cells, unable to
bind Tat, were used as a negative control. After 4 hours of
incubation at 37uC, cells were washed to remove excess plasmids
and transfection reagents, and grown at either 37uC or 39.5uC for
48 hours. We verified by Western Blot that Tat-Flag was
expressed in equal amounts at 37uC and 39.5uC (Fig. 5A).
Transactivation of the LTR was then assessed by measuring
luciferase activity in cell lysates. Activity of the LTRDTAR
promoter was very low, with or without Tat, and hyperthermia
had no effect on this residual activity (Fig. 5B). Tat efficiently
stimulated the full length LTR, and this transactivation was
significantly higher at 39.5uC than at 37uC (2 fold increase,
Fig. 5B). The greater transactivation of the LTR at 39.5uC was not
caused by a higher production of transfected Tat (Fig. 5A), by
changes in Tat nuclear localization (not shown) nor by a trans-
effect of secreted Tat by neighboring cells (Fig. S1B). In contrast to
Figure 3. Hyperthermia increases infection with single-cycle HIV-1 but not with a GFP lentivector. A: Infection of Jurkat cells with single-
cycle HIV. One representative experiment is shown. Cells were infected with 5, 20, or 100 ng Gag p24 of Denv(VSV)/mL/106 cells for 2 hours at 37uC or
39.5uC, washed, and grown at 37uC or 39.5uC. Gag levels were assessed by flow cytometry at 24 hours p.i. B: Infection of P4C5 cells with single-cycle
HIV. One representative experiment is shown. 86104 P4C5 cells were plated in 96-well plates. Cells were infected in triplicates with 1 or 5 ng Gag p24
of Denv(VSV) and grown at 37uC or 39.5uC. Infection was assessed 36 hours p.i. by measuring b-Galactosidase activity (570 nm OD). C: Mean6 SD of 4
independent experiments. P4C5 cells were infected with 1 ng Gag p24 of the indicated HIV strains. Statistical significance was assessed by the Mann-
Withney test. p,0.05(*). D: Infection of P4C5 cells at different temperatures. One of two representative experiments is shown. Data are mean6 SD of
triplicates. Using the same protocol as in B, cells were infected with 5 ng Gag p24 of NL4-3 and grown at the indicated temperatures. E: Transduction
of P4C5 and Jurkat cells with a GFP expressing lentivector (LV-GFP). One of three representative experiments is shown. P4C5 or Jurkat cells were
transduced with 1, 10 or 100 ng Gag p24/mL/106 cells of LV-GFP. GFP levels were measured 24 hours later by flow cytometry.
doi:10.1371/journal.ppat.1002792.g003
Fever and HIV
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its action on the LTR promoter, hyperthermia did not significantly
impact the activity of a CMV promoter, upon transfection of a
pCMV-b-Galactosidase reporter plasmid (not shown). Therefore,
a more potent activation of the LTR by Tat likely facilitates HIV-1
replication at 39.5uC.
Hyperthermia boosts HIV-1 reactivation from latency in J-
Lat cells
The existence of latent HIV-1 reservoirs is a long-standing issue
in the treatment of AIDS. The formation of these reservoirs is not
prevented by Highly Active Antiretroviral Therapy (HAART) and
drives viral re-emergence if therapy is stopped [56], [57], [58],
[59], [60]. Reactivation from latency is a highly regulated process.
Earlier studies outlined the impact of the site of integration, the
role of pro-inflammatory cytokines, transcription factors like
NFkB, and epigenetic modifications such as cytosine methylation
[61], [62], [63], [64], [65]. We asked whether hyperthermia could
trigger HIV-1 reactivation from latency, directly or in synergy with
other stimuli. To this aim, we used the J-Lat 10.6 model [66].
Briefly, J-Lat 10.6 are Jurkat cells, carrying a latent, integrated
provirus, where env is deleted and nef replaced by gfp. Without
activation, GFP is not produced, but treatment with TNFa, PMA,
or other molecules, induces HIV-1 reactivation and GFP
expression. As outlined Fig. 6A, J-Lat 10.6 cells were exposed to
various stimuli, and grown at 37uC or 39.5uC for 24 hours. Viral
reactivation was then followed by measuring the appearance of
GFP+ cells by flow-cytometry.
A representative experiment is shown Fig. 6B, and the mean of
all experiments in Fig. 6C. Alone, hyperthermia was not sufficient
to trigger viral reactivation (,2% of GFP+ cells at both
temperatures). As a positive control, we used TNFa, which
induced viral reactivation in up to 80% of J-Lat 10.6 cells (Fig. 6).
Even used at sub-optimal concentrations, TNFa and PMA
induced a similar reactivation at 37uC or 39.5uC (Fig. S2 and
Figure 4. Hyperthermia does not stimulate viral fusion and reverse transcription. A: Viral fusion assay. One representative experiment is
shown. Jurkat cells were exposed for 2 hours at 37uC or 39.5uC to 5 or 100 ng Gag p24/105 cells/0.1 mL of either WT, or a non fusogenic env mutant
(F552Y) NL4-3, both bearing the chimeric protein b-lactamase-Vpr. Viral access to the cytoplasm was assessed by flow cytometry, using the ability of
b-lactamase to cleave CCF2-AM, a fluorogenic substrate. B: Mean 6 SD of 3 independent experiments. C: In vitro assessment of RT activity. Mean 6
SD of 2 independent experiments is shown. HIV-1 NL4-3 virions were lysed and incubated at 37uC or 39.5uC for 1 h or 3 h. RT activity was measured
with the Innovagen RetroSys RT Activity Kit (405 nm OD). D: Viral DNA synthesis in Jurkat cells. Mean 6 SD of 3 independent experiments is shown.
Jurkat cells were infected with 50 ng or 250 ng Gag p24 of Denv(VSV)//mL/106 cells for 2 hours at 37uC or 39.5uC, washed, and grown at 37uC or
39.5uC. 8 hours p.i., cells were harvested and viral DNA was measured by quantitative PCR. As a control, the RT inhibitor nevirapine (NVP) was added
during infection.
doi:10.1371/journal.ppat.1002792.g004
Fever and HIV
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not shown), suggesting that these stimulators may be too strong to
evidence any difference. We then used a more physiological
stimulation, by exposing J-Lat 10.6 cells to conditioned medium
from PBMCs. Supernatants from non stimulated PBMCs (but
treated with IL-2 to avoid massive cell death), as well as from
PHA-activated PBMCs, induced GFP expression in J-Lat 10.6
cells at 37uC (5% and 22% of GFP+ cells, respectively).
Noteworthy, supernatants from PHA-activated PBMCs were
more potent than that from non-stimulated PBMCs. This suggests
that reactivation in J-Lat 10.6 cells is mediated by cytokines or
other molecules that are up-regulated in activated PBMCs.
Interestingly, PBMCs supernatants were more potent when J-Lat
10.6 cells were incubated at 39.5uC, with a significant 2-fold
increase in the levels of GFP-expressing cells. We then directly co-
cultivated J-Lat 10.6 cells with PBMCs. Co-culture with IL-2-
treated PBMCs efficiently reactivated J-Lat cells, with up to 17%
of GFP+ cells (Fig. 6B). Hyperthermia further increased this effect
by 2-fold. Co-culture with PHA-activated PBMCs resulted in high
levels of cell death (not shown).
There are different J-Lat clones, in which the extent of viral
reactivation varies according to the viral integration site [62]. To
check that the effect of hyperthermia on viral reactivation was not
restricted to the 10.6 clone, we used J-Lat 6.3, J-Lat 8.4 and J-Lat
9.2 cells. These clones are less susceptible to reactivation than the
10.6 clone [62]. Indeed, we did not detect viral reactivation
following exposure to PBMCs conditioned medium nor co-culture
with PBMCs (not shown). However, stimulation with various doses
of TNFa resulted in viral reactivation in J-Lat 6.3, J-Lat 8.4 and J-
Figure 5. Hyperthermia enhances Tat-dependent LTR transcription. A: Levels of Tat in HeLa-LTR-Luc cells. Cells were transfected with 20 ng
of Tat-Flag. After 4 hours at 37uC, cells were washed and grown at 37uC or 39.5uC for 48 hours. Tat-Flag and tubulin levels were assessed by Western
Blot. B: LTR activity in HeLa cells at 37uC or 39.5uC. HeLa-LTR-Luc and HeLa-LTRDTAR-Luc cells were transfected with 4 ng or 20 ng of Tat-Flag. After
4 hours at 37uC, cells were washed and grown at 37uC or 39.5uC. 48 hours later, luciferase levels were measured and normalized to protein
concentration. Data are mean 6 SD of 3 independent experiments. Statistical significance was assessed by the Mann-Withney test. p,0.05(*).
doi:10.1371/journal.ppat.1002792.g005
Fever and HIV
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Lat 9.2 cells, at a weaker level than in J-Lat 10.6 (Fig. S2).
Hyperthermia increased modestly but significantly the effect of
TNFa in J-Lat 6.3, J-Lat 8.4 and J-Lat 9.2 cells. To achieve similar
levels of GFP expression, the concentration of TNFa required at
37uC was two fold greater than at 39.5uC.
Altogether, these results show that PBMCs conditioned
medium, as well as a direct co-culture with PBMCs, induce viral
reactivation in the J-Lat model. Hyperthermia significantly
enhances this phenomenon.
Hsp90 mediates the stimulating effect of hyperthermia
on HIV-1 infection
Hsp90 may play a role during HIV-1 infection [48]. Chromatin
immunoprecipitation experiments recently revealed that Hsp90
associates with the viral LTR and may regulate gene expression
[48]. The underlying mechanisms are only partly understood, and
may involve an effect of Hsp90 on chromatin remodeling, to
facilitate transcription [48]. Moreover, the chaperone activity of
Hsp90 has been reported to promote formation of a functional P-
TEFb/Tat/TAR complex [67]. This prompted us to examine
whether Hsp90 co-localizes with actively transcribing provirus in
HIV-1-expressing cells. We used an original approach to directly
visualize viral RNA in living cells. The technique takes advantage
of an HIV-1 strain encoding an RNA which includes 24 binding
sites for the phage MS2 protein (HIV_Exo_246MS2) [68], [69],
[70]. U2OS cells carrying an integrated HIV_Exo_246MS2
genome (U2OS HIVexo) allow the visualization of nascent RNA
from a single chromatin location [68], [69], [70]. Upon Tat
expression, this RNA is synthesized and can be detected by specific
high-affinity interaction with the YFP-MS2nls reporter protein.
U2OS HIVexo cells were transfected with the YFP-MS2nls
reporter, with or without a Tat-expressing plasmid. After an
overnight incubation, the transcribing provirus and endogenous
Hsp90 were both visualized by immunofluorescence. In the
absence of Tat, YFP-MS2nls displayed a diffuse nuclear staining,
whereas the Hsp90 signal was mostly detected in the cytoplasm
with very little, if any, nuclear localization (not shown). With Tat,
the nascent HIV RNA was detected as a single bright spot of YFP-
MS2nls within the nucleus (Fig. 7A). Previous studies demonstrat-
ed that these spots represent true sites of viral transcription, rather
than sites of HIV RNA sequestration [68]. At 37uC, Hsp90 co-
localized with YFP-MS2nls in about 27% of the cells in which a
Figure 6. Hyperthermia increases viral reactivation in J-Lat 10.6 cells. A: Experimental outline. J-Lat 10.6 are Jurkat-derived cells carrying a
latent, integrated, provirus, encoding gfp instead of nef. Stimulation of J-Lat 10.6 cells with TNFa triggers HIV-1 reactivation and GFP expression. B:
Reactivation of J-Lat 10.6 cells with various stimuli. One representative experiment is shown. J-Lat 10.6 cells were treated with either TNFa,
supernatants from IL-2 treated or PHA-activated PBMCs, or co-cultivated with IL-2-treated PBMCs for 48 hours at 37uC or 39.5uC. Viral reactivation was
assessed by measuring GFP levels by flow cytometry. C: Mean 6 SD of 4 independent experiments. Statistical significance was assessed by a paired t
test. p,0.05(*).
doi:10.1371/journal.ppat.1002792.g006
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nuclear YFP-MS2nls bright spot was visible (Fig. 7B), indicating
Hsp90 can be recruited to the viral transcription site in HIV-
infected cells. Hsp90 co-localization with HIV transcripts was
significantly increased when cells were incubated overnight at
39.5uC, reaching 70% of the cells in which a viral transcription site
was visible (Fig. 7B).
We determined further the role of Hsp90 during hyperthermia.
We sought to silence Hsp90, but the extent of silencing achieved
with various siRNAs or shRNAs was partial, precluding further
analysis (not shown). We thus used a well-characterized pharma-
cological inhibitor of Hsp90, 17-AAG (also known as tanespimy-
cin) [71]. This compound is a geldanamycin-derived molecule,
inhibiting the ATPase activity of Hsp90 and blocking various
functions of the heat shock protein [71], [72], [73]. Interestingly,
17-AAG is known to reduce HIV-1 replication, but its effects were
studied so far at 37uC [48], [50]. We thus examined whether 17-
AAG reversed the stimulating effect of hyperthermia on HIV-1
replication. To this aim, P4C5 cells were exposed to increasing
doses of 17-AAG (20–250 nM) and infected with the single-cycle
Denv(VSV) virus. These 17-AAG concentrations were chosen
because they did not induce obvious cytotoxicity (not shown). This
is in agreement with a previous report indicating that the toxic
concentration (CC50) is about 2 mM [50]. At 37uC, 17-AAG
decreased infection, but this effect was modest, requiring 100–
250 nM concentrations of the inhibitor (Fig. 7C). Interestingly, the
compound was more active in hyperthermic cells, starting to
decrease the infectivity enhancement at 20 nM, and abrogating
this positive effect at 100 nM (Fig. 7C).
Figure 7. Role of Hsp90 during HIV-1 transcription and replication. A: Visualization of HIV transcription sites in U2OS HIVexo cells. One
representative cell (at 37uC), displaying a co-localization of Hsp90 and nascent HIV RNA (followed with a YFP-MS2nls reporter protein) is shown.
2.56105 U2OS HIVexo cells were plated on coverslips and grown overnight at 37uC. Cells were transfected with 50 ng of Tat and 300 ng of YFP-
MS2nls. After 4 hours, cells were washed and grown overnight at 37uC or 39.5uC. B: Mean 6 SD of 3 independent experiments. Cells showing a
transcription spot were scored for their co-localization with Hsp90. The percentage corresponds to cells in which HIV transcription sites co-localize
with Hsp90. Statistical significance was assessed by an unpaired t test p,0.05(*). C: effect of the Hsp90 inhibitor 17-AAG on single-cycle HIV infection
in P4C5 cells. Mean 6 SD of 4 independent experiments is shown. 26105 P4C5 cells were infected with 30 ng Gag p24 of Denv(VSV) for 2 hours at
37uC or 39.5uC, in presence of the indicated doses of 17-AAG. Cells were washed and grown at 37uC or 39.5uC at the indicated doses of 17-AAG. Cells
were harvested 24 hours p.i. and Gag levels were assessed by flow cytometry. As a negative control, we used DMSO at a concentration corresponding
to 250 nM 17-AAG.
doi:10.1371/journal.ppat.1002792.g007
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Therefore, Hsp90 is recruited to HIV-1 transcription sites, and
this process occurs more efficiently at 39.5uC. The Hsp90 inhibitor
17-AAG significantly decreases the stimulating effect of hyper-
thermia on HIV-1 infection.
Discussion
We report here a positive impact of hyperthermia on HIV-1
replication. Hyperthermia is known to enhance the functions of
immune cells and to confer protection against pathogen infection
[1], [2], [4], [5], Previous studies on temperature and HIV-1
mostly focused on chronically infected cell lines [31], [32] or used
non-physiological heat shock treatment to study viral reactivation
from latency (a few minutes at 42–45uC [33]). Here, we report that
elevation of temperature to fever-like levels (39.5uC) stimulates
HIV-1 replication in primary CD4+ T lymphocytes as well as in
Hela and Jurkat cell lines. In single-cycle infection assays,
hyperthermia increased HIV-1 infection by 2 to 7 fold. This
stimulation was apparently not due to unspecific alterations of
cellular metabolism, since cell growth, viability, or surface levels of
various molecules were not significantly affected by hyperthermia.
To get insight into how hyperthermia stimulates HIV-1
replication, we compared the efficiency of various steps of the
viral life cycle at 37uC and 39.5uC. Viral entry and fusion,
measured by the Vpr-b-lactamase assay, were similar at the two
temperatures. Enzymes have a range of conditions of pH, salt
concentration, and temperature, in which they display optimal
activity. We did not observe an effect of hyperthermia on reverse
transcriptase, as both in vitro catalytic activity of the enzyme and
the levels of viral DNA synthesis in infected cells were unchanged
by temperature. We then examined the influence of temperature
on the viral transcription step. Hyperthermia did not induce basal
LTR activity without Tat. However, in the presence of Tat,
hyperthermia lead to a significantly better transactivation of the
LTR. This is in line with earlier reports, demonstrating that a
transient heat shock at 42uC increases HIV-1 transcription in
monocytic cells lines [31], [32]. Noteworthy, the activity of the
CMV promoter was not increased at 39.5uC (not shown),
suggesting that hyperthermia does not trigger a global increase
of cellular transcription. Accordingly, the steady state levels of
several cellular proteins (actin, CD4, ICAM-1, MHC-I, etc.) were
apparently similar at normal and elevated temperatures.
To characterize the molecular mechanism by which hyperther-
mia up-regulates HIV-1 infection and transcription, we examined
the role of Hsp90. This protein exerts diverse functions in normal
and stressed cells, through its ATPase activity and its protein
binding domain [72], [73]. It acts as a chaperone for many cellular
proteins. Hsp90 assists folding, assembly, intracellular transport,
maintenance and degradation of proteins, and regulates cell
signaling and cell cycle [74], [75]. Hsp90 is involved in HIV-1
infection at 37uC, regulating viral gene expression [48]. Hsp90
also impacts the replication of other viral species, such as Human
Cytomegalovirus, Influenza Virus, Flock House Virus and
Hepatitis C Virus [76], [77], [78], [79]. We show here that the
levels of Hsp90 are augmented at 39.5uC, in primary lymphocytes
and other cells (Fig. 2 and not shown). By using an immunoflu-
orescence technique allowing the visualization of nascent viral
RNA in living cells, we demonstrate that, in presence of Tat,
Hsp90 can be found in the nucleus, at HIV-1 transcription sites.
This localization was rather infrequent at 37uC, but was
significantly increased at 39.5uC (27% and 70% co-localization,
respectively). Furthermore, 17-AAG, a pharmacological inhibitor
of Hsp90, reversed the stimulating effect of hyperthermia on
single-cycle infection in P4C5 cells. Altogether, these results point
out for a previously uncharacterized role of Hsp90, facilitating
HIV-1 transcription and replication at 39.5uC. It will be worth
further dissecting how Hsp90 acts on viral transcription at this
temperature. One can speculate that the chaperone protein may
bind more efficiently to the P-TEFb/Tat/TAR transcription
complex [67] and thus increase its activity, and/or may enhance
chromatin modeling and accessibility to the viral promoter [48].
Mechanisms regulating HIV-1 gene expression are also
involved in viral reactivation from latency [80]. We show here
that the conditioned medium from PBMCs induced viral
reactivation, in the J-Lat 10.6 model of latently infected T cells.
Strikingly, reactivation was more pronounced at 39.5uC than at
37uC. Futures studies will help understanding which cytokines or
other molecules produced by PBMCs mediate this effect. For
instance, heat shock at 42uC is known to act in synergy with IL-6
to induce viral reactivation in a latently infected monocytic cell-
line [31]. It will be of interest to compare the stimulating effect of
IL-6 and other cytokines, at normal and fever-like temperatures,
not only in J-Lat cells, but also in other models of viral latency
(PBMCs from HAART-treated patients, or latently-infected,
resting primary CD4+ T cells [81]).
In this study, we have focused our analysis of the effect of
temperature on a few key steps of the viral life cycle. We
demonstrate that hyperthermia globally facilitates viral replication.
At 39.5uC, viral entry, fusion and reverse transcription occur
normally, whereas Tat-mediated transactivation of the LTR is
significantly more efficient. It has been previously reported that the
activity of HIV-1 integrase and protease is not increased at 39.5uC
[35]. This does not rule out the possibility that other steps of HIV-
1 infection (nuclear import, selection of integration sites in the
cellular genome, viral translation, assembly, release, etc.) might be
positively or negatively modified at a fever-like temperature.
What is the physiological relevance of our observations? Patients
treated with HAART and with controlled viremia can experience
transient bursts of HIV-1 replication termed viral blips [82].
Furthermore, co-infections are frequent in HIV-1-positive indi-
viduals and are often associated with fever and acute illnesses [83].
For instance, Plasmodium falciparum, the causative agent of malaria,
induces recurrent, strong episodes of fever lasting 2–3 days, which
correlates with increased viral loads [84]. The origin of these viral
blips, or of other more pronounced viral rebounds is likely multi-
factorial. Our results suggest that fever may directly stimulate viral
replication or reactivation from latent reservoirs, in association
with other inflammatory or immunological events.
Materials and Methods
Cells, viruses, reagents
Jurkat (clone 20), MT4C5, J-Lat (clone 6.3, 8.4, 9.2 and 10.6),
PBMCs and primary CD4+ T cells were grown in RPMI 1640
with Glutamax, supplemented with 10% heat-inactivated Fetal
Bovine Serum (FBS) and antibiotics. HEK-293T, U2OS HIVexo
[68], HeLa, HeLa Tat, and P4C5 cells were grown in Dulbecco
modified Eagle medium (DMEM) supplemented with 10% heat-
inactivated FBS and antibiotics. For P4C5 cells, a HeLa-derived
cell line expressing CD4, CCR5, and harboring a LTR-lacZ
reporter cassette, G418 (500 mg.mL21, Sigma) and Hygromycin B
(50 mg.mL21, PAA) were added to the culture medium. HeLa
expressing Tat were grown in presence of Methotrexate (2 mM,
Sigma). Primary CD4+ T cells were purified from human
peripheral blood by Ficoll centrifugation, followed by immuno-
magnetic selection (Miltenyi Biotec). The blood was provided by
the EFS (Etablissement Franc¸ais du Sang, the French Official
Blood Bank). About 98% of cells were CD4+ CD3+. For
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activation, primary CD4+ T cells were treated with phytohemag-
glutinin (PHA, 1 mg.ml21, Remel Europe LTD) for 24 hours and
then cultured in interleukin 2 (IL-2)-containing medium
(50 U.mL21, Abcys). If not stated different, cells were grown at
37uC, 5% CO2. Cells grown at 39.5uC were cultivated in a distinct
incubator. Temperature was monitored by 2 different thermom-
eters. HIV-1 strains, including NL4-3 and NLAD8, were
produced by calcium-phosphate transfection of HEK-293T cells.
The primary isolate 132W [85] was produced by infection of
MT4C5 cells. Vesicular stomatitis virus type G (VSV-G)
pseudotyped viruses were generated by co-transfection of HEK-
293T cells with the NL4-3 provirus and VSV-G expression
plasmid (8:1 ratio). For the production of Blam-Vpr containing
viruses, HEK-293T cells were co-transfected with NL4-3 or NL4-
3-F522Y proviruses along with a Blam-Vpr expression plasmid
(3:1 ratio), kindly provided by Warner Greene [52], [51]. NL4-3-
F552Y provirus encodes a non-fusogenic gp120/g41 Env complex
[86]. LV-GFP were produced by co-transfection of HEK-293T
cells by the packaging plasmid (R8-2), the GFP plasmid (pTrip-
GFP) and VSV-G expression plasmid (5:5:1 ratio). Nevirapine
(NIH Catalog, nu4666, batch 01990) was used at 25 nM. 17-AAG
(Enzo Life Sciences) was diluted in DMSO and used at the
indicated concentrations.
Intracellular and surface molecule stainings
Cell surface stainings were performed at 4uC for 30 min with
the following monoclonal antibodies (mAbs): ICAM-1 (clone 1H4,
Immunotools, dilution 1/20), CD11a (Immunotools, 1/10), CD18
(Immunotools, 1/10), CD69 (clone FN50, BD, 1/30), MHC-I
(clone W632, Sigma, 1/100), HLA-A2 (clone BB7.2, BD, 1/50),
CD4 (clone SK3, BD, 1/30), CXCR4 (clone 12G5, NIH AIDS
Research and Reference reagent Program, 1/100), Goat anti-
Mouse Alexa 647 (Invitrogen, 1/400). Isotype-matched mAbs
were used as negative controls. Cells were fixed in PBS-
paraformaldehyde (PFA, Sigma) 4% for 5 min. For quantification
of Gag levels, cells were harvested at indicated time points and
fixed in PBS-PFA 4% for 5 min. Cells were washed in PBS and
stained for 30 min in PBS containing 1% BSA (Sigma),
50 mg.mL21 saponin (Sigma), and the anti-Gag antibody (clone
KC57, 1/500, Beckman Coulter). Fluorescence was assessed by
flow cytometry on a FacsCanto II (BD).
Western Blot
Cells transfected with 20 ng of Tat-Flag were lysed with passive
lysis buffer (Promega) and probed by Western Blot for Tubulin
(T9026, Sigma, 1/5000) and Tat (Flag antibody, F3165, Sigma,
1/5000). Cells cultured for 8 hours at 37uC or 39.5uC were lysed
in PBS Triton 1% in presence of a proteases inhibitors cocktail
(Roche) and probed by Western Blot for Actin (clone AC-15,
Sigma, 1/5000), Hsp70 (clone W27, Santa Cruz, 1/200) and
Hsp90 (clone 68, BD, 1/1000, kindly provided by Jean-Michel
Heard).
Single-cycle infection assays
One day before infection, 86104 P4C5 cells were plated in 96-
well plates. Cells were infected in triplicate with 1 or 5 ng Gag p24
per well. Cells were lysed in PBS 0.1% NP40 5 mM MgCl2
36 hours post-infection, and incubated at room temperature with
Chlorophenol Red-b-D-Galactopyranoside (CPRG, Roche) at a
final concentration of 3.65 mg.mL21. 570 nm OD was measured
every 15 min. Jurkat cells were infected with 5, 20 or 100 ng Gag
p24/mL/106 at 37uC or 39.5uC for 2 hours. Cells were washed in
PBS and grown at either 37uC or 39.5uC. Gag or GFP levels were
assessed by flow cytometry 24 hours p.i.
Viral replication assays in Jurkat and primary CD4+ T cells
Jurkat or primary CD4+ T cells (16106) were infected with the
indicated doses of NL4-3 for 2 hours at 37uC or 39.5uC, washed
once in PBS, and grown at 37uC or 39.5uC. Medium was changed
every 2–3 days and samples were harvested at the indicated time
points. Gag levels were assessed by flow cytometry. To combine
results from independent experiments, we have measured the area
under the curve at 37uC and 39.5uC. In Jurkat cells, there is no
real peak of viral replication, since most of the cells (.80%) may
get infected, and then die. In primary CD4+ T cells, a peak of
infected cells may be detected, probably because a fraction of the
cells is not sensitive to infection. We have thus calculated the area
under the curve for all time points in Jurkat, and for time points
occurring until the appearance of the peak at 39.5uC in primary
CD4+ T cells.
Luciferase assay
HeLa LTR-Luc cells contain a single copy of integrated HIV-1
LTR-luciferase reporter construct [87] and were transfected with
4 ng or 20 ng of pcDNA-Tat-Flag completed to 2 mg pcDNA3.1,
or pcDNA3.1 alone, using JetPEI reagent (Polyplus) in 6 well
plates. After 4 hours at 37uC, cells were washed and grown at
37uC or 39.5uC. 48 hours after incubation, cells were lysed using
Passive Lysis Buffer (Promega) and luciferase activity was
measured according to the manufacturer’s protocol (Promega).
Luciferase activity was normalized to protein concentration using
Bradford assay (Biorad).
Blam-Vpr assay
Viral entry was assessed by a test adapted from Cavrois et al.
[51], [52]. Briefly, 5 or 100 ng Gag p24 of ultracentrifuged virions
containing the Blam-Vpr fusion protein were used to infect
1.56105 Jurkat cells at 37uC or 39.5uC in a minimal volume
(100 mL), in presence of 10 mM Hepes and 2 mg.mL21 DEAE
Dextran (Sigma). After 2 hours, cells were washed in cold CO2-
independent medium (Invitrogen), without FBS, resuspended in
cold CO2-independent medium supplemented with 10% FBS and
incubated with the CCF2-AM substrate (CCF2-AM kit, Invitro-
gen), in the presence of 1.8 mM Probenecid (Sigma), for 2 hours.
Cells were extensively washed in cold CO2-independent medium
and fixed in PBS-PFA 4% for 5 min. The cleaved CCF2-AM
fluorescence (excitation at 405 nm, emission at 450 nm) was then
immediately measured by flow cytometry using the DAPI channel,
on a FacsCanto II (BD).
In vitro RT enzymatic assay
NL4-3 virions were lysed in PBS NP40 0.08% and incubated
with Retrosys RT Activity Kit (Innovagen) substrates for 1 or
3 hours, according to the manufacturer’s indications. RT activity
was measured with a alcaline phosphatase readout (405 nm OD).
Quantification of HIV-1 DNA
Jurkat cells were infected with 50 or 250 ng Gag p24 at 37uC or
39.5uC with NL4-3 Denv(VSV). After 2 hours, cells were washed
and grown at 37uC or 39.5uC. Cells were harvested 8 hours p.i.
and lysed in AL Buffer (Qiagen) in presence of Proteinase K
(Qiagen) for 1 hour at 56uC. Total DNA was extracted from by
phenol-chloroform extraction and ethanol precipitation. To
remove all traces of plasmidic DNA, samples were treated with
DpnI Fast Digest (Fermentas) for 15 min at 37uC. To avoid
inhibition of the PCR reaction by DpnI reaction buffer, samples
were diluted 40 times in pure water (Gibco). Early RT products
(amplicon length: 183 bp) were quantified by real-time PCR with
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the primers M667 (GGC TAA CTA GGG AAC CCA CTG) and
AASM (GCT AGA GAT TTT CCA CAC TGA CTA A) using
the the following program: 35 cycles 10 s 95uC, 10 s 57uC, 15 s
72uC. For late RT products (amplicon length: 200 bp), we used
the primers M667 and M661 (CCT GCG TCG AGA GAG CTC
CTC TGG), with a slightly different PCR program (35 cycles, 10 s
95uC, 15 s 57uC, 15 s 72uC). The number of cells was calculated
by quantification of genomic GAPDH (amplicon length: 303 bp),
using the same program as late RT products and the following
primers: forward (GGG AAA CTG TGG CGT GAT) and reverse
(GGA GGA GTG GGT GTC GTT).
Viral reactivation assay
J-Lat clones 6.3, 8.4, 9.2 and 10.6, kindly provided by Ste´phane
Emiliani, have been previously described [66]. Briefly, J-Lat are
Jurkat cells with a latent, integrated, and env-deleted provirus,
encoding gfp instead of nef. Stimulation of J-Lat cells with
recombinant TNFa (Peprotech) or other molecules such as PMA
triggers HIV-1 reactivation. PBMCs were isolated from peripheral
blood, PHA-activated or treated with IL-2 for 3 days. Superna-
tants were then collected and used to stimulate J-Lat cells. Serial
dilutions of supernatants were tested, as raw supernatants were
sometimes toxic. For co-cultures experiments, PBMCs were
isolated from peripheral blood, treated for 3 days with IL-2, and
co-cultivated with Far-Red labelled J-Lat 10.6 cells at a 1:4 ratio in
IL-2-containing medium. 48 hours after stimulation, cells were
harvested, fixed in PBS-PFA 4%. Viral reactivation was followed
by appearance of GFP+ J-Lat cells by flow-cytometry.
Localization of HIV-1 transcription sites by
immunofluorescence
U2OS HIVexo cells were transfected with a Tat-expressing
plasmid to stimulate viral gene expression. The transcribing
provirus was detected by MS2 tagging, Hsp90 was detected by
immunofluorescence with a monoclonal antibody. YFP-MS2nls,
yellow fluorescent protein fused to MS2 with a nuclear localizing
signal. U2OS HIVexo cells and plasmids for Tat and EYFP-
MS2nls expression were described previously [68]. 2.56105 cells
were plated on coverslips and grown overnight at 37uC. Next day,
cells were transfected (Lipofectamine LTX, Invitrogen) with
plasmids expressing Tat (50 ng) and YFP-MS2nls (300 ng). After
4 hours cells were washed and shifted to an incubator at 39.5uC in
medium containing 25 mM Hepes for 20 hours. Control cells
were kept at 37uC also with 25 mM Hepes in sealed flasks. After
treatment, cells were fixed and treated for immunofluorescence
essentially as described [88] with a mouse mAb (H90-10, Abcam,
1/500). Cells showing a transcription spot were scored for their co-
localization with Hsp90 on a confocal microscope Zeiss 510
META.
Statistical analyses
Statistical tests were performed with GraphPad Prism 5.
Supporting Information
Figure S1 Hyperthermia does not alter half-life of
virions and does not promote Tat bystander effect. A:
Half life of viral preparations at 37uC and 39.5uC. Viral
preparations were incubated in medium at 37uC or 39.5uC for
the indicated times (from 15 min to 24 hours). P4C5 cells were
infected in triplicates with 1 ng Gag p24 and grown at 37uC.
Infection was assessed 36 hours p.i. by measuring b-Galactosidase
activity (570 nm OD). The background OD, corresponding to
non-infected cells is indicated in grey. The half-life was calculated
as 50% of the initial infectivity. One of three representative
experiments is shown. Data are mean 6 SD of triplicates. B: Co-
culture of HeLa Tat and P4C5 cells. 8000 P4C5 cells were co-
cultured with 1000, 2000, 4000 or 8000 HeLa Tat cells at 37uC or
39.5uC. After 16 hours of co-culture, cells were lysed and the trans-
effect of secreted Tat on the LTR promoter was assessed by
measuring b-Galactosidase activity (OD). HeLa Tat cells express
functional Tat protein, as assessed by transfecting a LTR-
luciferase reporter plasmid (not shown). One of three representa-
tive experiments is shown.
(TIF)
Figure S2 Hyperthermia enhances TNFa-mediated viral
reactivation in several J-Lat clones. J-Lat 6.3, J-Lat 8.4, J-
Lat 9.2 or J-Lat 10.6 cells (16105 per well) were stimulated at
37uC or 39.5uC with the following doses of recombinant TNFa:
0.5; 5 or 10 ng.mL21. Viral reactivation was assessed 48 hours
later by measuring GFP levels by flow cytometry. Data are mean
6 SD of 4 independent experiments. Statistical significance was
assessed by a paired t test. p,0.05(*).
(TIF)
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